Focused On-demand Library for Guanine nucleotide-binding protein subunit beta-4

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries.


 

Fig. 1. The screening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
Q9HAV0

UPID:
GBB4_HUMAN

ALTERNATIVE NAMES:
Transducin beta chain 4

ALTERNATIVE UPACC:
Q9HAV0; B3KMH5; D3DNR8

BACKGROUND:
The Guanine nucleotide-binding protein subunit beta-4, known alternatively as Transducin beta chain 4, is integral to various transmembrane signaling pathways. It ensures the proper functioning of G proteins by enabling GTPase activity, the exchange of GDP for GTP, and interactions between G proteins and effectors. Its critical role in signal transduction highlights its potential as a therapeutic target.

THERAPEUTIC SIGNIFICANCE:
Linked to Charcot-Marie-Tooth disease, dominant intermediate F, Guanine nucleotide-binding protein subunit beta-4's involvement in this genetic disorder suggests its potential as a target for therapeutic intervention. Exploring its function could lead to breakthroughs in treating or managing this progressive muscle weakness condition.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 965 of 8789